Fig. 5From: Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trialEffect size of each time point group of responders and non-responders compared with RBX2660. Effect size is expressed as a modified Cramer criterion, ϕ, for each pairwise comparisonBack to article page